Interim report
Page 1
August 11 , 2026 R TM Half - Year Financial Report JANUARY - JUNE 2026 Remedy Entertainment Plc
Page 2
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 2 (22) Remedy Entertainment Plc | Stock exchange release | August 11, 2026, at 09:00 a.m. EEST Remedy Entertainment Plc | Half-Year Financial Report January–June 2026 CONTROL Resonant set to launch on September 24th Marketing ramped up while revenue decreased The Half-Year Financial Report is unaudited. Figures in parentheses refer to the comparison period in the previous year, unless otherwise stated. Highlights from April–June 2026 • Revenue decreased by 40.0% to EUR 10.2 (16.9) million. • EBITDA was EUR -2.4 (4.2) million. • Operating profit (EBIT) was EUR -3.9 (-0.5) million, and the operating profit margin was -38.8% (-2.7%) of revenue. • Cash flow from operations was EUR -0.7 (3.1) million. • In June 2026, Remedy announced that CONTROL Resonant will launch worldwide on September 24, 2026. Highlights from January–June 2026 • Revenue decreased by 23.1% to EUR 23.3 (30.3) million. • EBITDA was EUR 0.5 (6.8) million. • Operating profit (EBIT) was EUR -2.9 (0.8) million, and the operating profit margin was -12.5% (2.8%) of revenue. • Cash flow from operations was EUR 7.6 (-3.5) million. • In February 2026, Jean-Charles Gaudechon was appointed as the CEO of Remedy as of March 1, 2026.
Page 3
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 3 (22) Key Figures MEUR, IFRS, Group, unaudited 4–6/2026 4–6/2025 1–6/2026 1–6/2025 1–12/2025 Revenue 10.2 16.9 23.3 30.3 59.5 Change in revenue, % -40.0% 63.5% -23.1% 43.4% 17.5% EBITDA -2.4 4.2 0.5 6.8 11.3 EBITDA, % of revenue -23.6% 24.9% 2.3% 22.4% 19.1% Operating profit (EBIT) -3.9 -0.5 -2.9 0.8 -14.9 Operating profit, % of revenue -38.8% -2.7% -12.5% 2.8% -25.0% Result for review period -3.2 -0.6 -2.8 0.0 -13.0 Result for review period, % of revenue -31.9% -3.4% -11.9% 0.1% -21.9% Balance sheet total 85.1 97.5 85.1 97.5 87.5 Cash flow from operations -0.7 3.1 7.6 -3.5 4.5 Net cash 11.8 10.0 11.8 10.0 11.1 Cash and liquid investments 29.6 27.6 29.6 27.6 29.4 Net gearing, % -21.4% -14.4% -21.4% -14.4% -19.7% Equity ratio, % 65.3% 72.8% 65.3% 72.8% 67.4% Capital expenditures 3.8 5.5 7.1 9.2 14.3 Average number of personnel during review period (FTE) 372 370 373 366 371 Headcount at the end of period 379 385 379 385 387 Earnings per share, € -0.24 -0.04 -0.20 0.00 -0.96 Earnings per share, € (diluted) -0.24 -0.04 -0.20 0.00 -0.96 Number of shares at the end of period 13,640,451* 13,640,451 13,640,451* 13,640,451 13,640,451* *Includes 50,000 treasury shares.
Page 4
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 4 (22) Comments by CEO Jean-Charles Gaudechon Remedy’s second quarter was defined by our announcement of the launch date for CONTROL Resonant. Marketing for CONTROL Resonant ramped up during the second quarter, reducing the profitability of the reporting period, as anticipated. Revenue was EUR 10.2 (16.9) million, decreasing 40.0% from the comparison period. Revenue from game sales and royalties was EUR 3.8 (9.5) million. The comparison period included revenue related to the launch of FBC: Firebreak, including initial accruals from subscription service agreements. Development fees, originating from Max Payne 1&2 remake and CONTROL Resonant, were EUR 6.4 (7.4) million. EBITDA was EUR -2.4 (4.2) million and operating profit (EBIT) was EUR -3.9 (-0.5) million. CONTROL Resonant CONTROL Resonant's September 24, 2026, launch date was revealed in a trailer at a State of Play presentation in June, followed shortly after by a second trailer at Summer Game Fest 2026. These trailer reveals lifted our media embargo, and the first hands-on previews of the game were published. The early reception has been very strong. CONTROL Resonant drew a lot of praise as media and content creators went hands-on with a significant portion of the game during Q2. The move to faster, melee-led action was the most debated aspect following the announcement, and it has since become one of the most consistently acclaimed elements of the game, alongside its atmosphere, storytelling and overall feel. Throughout the second quarter, our development team has continued to raise the quality of the whole experience, and we are confident that these elements are coming together into a spectacular title. Interest in the game reflects the positive feedback on its quality. As of August 11th, 2026, we have over 1.5 million wishlists across platforms. Pre-orders opened with healthy momentum, and our data indicates the game is tracking well against comparable titles in its launch window. We are seeing positive traction both in our traditional and growth markets. During the campaign window after the pre-order announcement, on PlayStation, our analytics show CONTROL Resonant ranking among the top three pre-ordered games in the US, Germany and Brazil. It has been encouraging to see Remedy's voice resonate broadly with players as we advance in our self-publishing strategy. Our first priority is to ship an outstanding game, and that guided how we selected the release date. We position CONTROL Resonant as a must-have day-one purchase while also building CONTROL into a lasting franchise. In a competitive autumn window, we believe the distinctiveness and quality of the game will make it stand out. CONTROL Resonant will be available across all major platforms from day one and is priced attractively for an AAA title. Combined with the release window becoming slightly less crowded since our original reveal, we remain confident in our positioning.
Page 5
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 5 (22) Games in the market Control continued its sales momentum in Q2 and delivered growth to the comparison period. Trailer reveals, release date and live pre-orders for CONTROL Resonant are renewing interest in the original game which continues to be an important entry point into the CONTROL franchise for new fans. Alan Wake 2’s consumer sales continued at an expected pace alongside Alan Wake Remastered. In the second quarter, royalties from both titles were generated entirely by consumer sales and there were no platform deal accruals. Alan Wake 2's lifetime sales exceeded 3 million copies during Q2. Rest of the games in the Alan Wake franchise sold at a normal back-catalogue pace. Decline in game sales and royalties was mainly caused by FBC: Firebreak’s launch in the comparison period. In the second quarter, most of FBC: Firebreak’s sales were revenue accruals from subscription service agreements. Heading to an important second half In the second half of 2026, years of work come together in September with the release of CONTROL Resonant: expanding the CONTROL franchise by developing and self- publishing the sequel, with our own voice. Our early indicators put the game alongside the industry's major releases. The weeks ahead are about execution. Early signals and commercial metrics give us confidence in the game's potential, but our focus remains on bringing an outstanding game to the market and letting the results speak. I personally see the game getting stronger week by week and our marketing accelerates further in the third quarter. Along the road to our largest and most ambitious release to date, our existing catalogue has provided a solid backbone and our other development projects advanced in line with plans, with our new project moving to production readiness. I want to thank the entire studio for its outstanding work and dedication. Games in development Game Publisher Stage-gate status CONTROL Resonant Remedy Entertainment Full production New project Remedy Entertainment Production readiness Max Payne 1&2 remake Rockstar Games Full production
Page 6
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 6 (22) Outlook 2026 (unchanged) Remedy expects its full year revenue and EBITDA to increase from the previous year. Long-term business prospects We have two established own franchises, CONTROL and Alan Wake, which are linked through the Remedy Connected Universe. Remedy will self-publish upcoming games, in which Remedy owns the IP. Growing and expanding the two franchises will be a key part of our future. In addition, we work with a partner franchise Max Payne, originally created by Remedy. By 2030, we aim to be a highly regarded creative studio with sustainable, significant commercial success. We have set ourselves the following financial targets: 1) Double the 2024 revenue by 2027 with continued growth beyond this milestone and 2) EBITDA margin of 30% by 2027 and maintain that minimum level throughout the strategy period. Webcast Remedy will host a webcast in English on its H1 2026 financial results for investors, analysts and media on August 11, 2026, at 12:00 p.m. (EEST). Remedy’s financial results will be presented by CEO Jean-Charles Gaudechon and CFO Santtu Kallionpää. The Half-Year Financial Report will be available after publication on Remedy’s Investor website: https://investors.remedygames.com/financials-and-reports/financial-reports/. Webcast details: Register in advance for the webcast: https://remedy.videosync.fi/q2-2026/register After registering, you will receive a confirmation email containing information about joining the webcast. A recording of the webcast will be available afterwards on Remedy’s Investor website: https://investors.remedygames.com/financials-and-reports/financial-reports/. More information Aapo Kilpinen, Investor Relations & Business Development Manager Phone: +358 44 522 0595 Email: aapo.kilpinen@remedygames.com
Page 7
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 7 (22) Remedy in brief Remedy Entertainment Plc is a pioneering, globally renowned video game company founded in 1995 and headquartered in Finland with an office in Stockholm, Sweden. Known for its story-driven and visually stunning action games, Remedy has created multiple successful, critically acclaimed franchises such as CONTROL, Alan Wake and Max Payne. Remedy also develops its own Northlight game engine and tools technology that powers its games. Remedy’s shares are listed on Nasdaq Helsinki’s main list. www.remedygames.com
Page 8
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 8 (22) Result from business operations April–June 2026 In April‒June 2026, Remedy’s revenue was EUR 10.2 (16.9) million, decreasing by 40.0% from the comparison period. Development fees were EUR 6.4 (7.4) million, and game sales and royalties were EUR 3.8 (9.5) million. While both development fees as well as game sales and royalties decreased from the comparison period, the decrease in revenue was mainly driven by the initial revenue accruals related to the launch of FBC: Firebreak in Q2 2025. For the reporting period, the main sources of revenue were development fees from Max Payne 1&2 remake and CONTROL Resonant as well as game sales from Control. Period also included game sales from FBC: Firebreak, mainly consisting of subscription service agreement accruals, and royalties from Alan Wake 2. In April‒June 2026, Remedy's EBITDA was EUR -2.4 (4.2) million and operating profit (EBIT) was EUR -3.9 (-0.5) million. Materials and services expenses, at EUR 1.6 million, were EUR 2.0 million lower than in the comparison period, driven by lower external development expenses in the game projects. Personnel expenses, at EUR 6.7 million, were 4.8% higher than in the comparison period. While the average number of personnel also increased by 0.5%, the main drivers of the increase in personnel expenses were general increase in salary levels and additional efforts ahead of the approaching game launch. Depreciation expenses were EUR 1.6 million, being EUR 3.1 million lower than in the comparison period, as the depreciation related to capitalized development expenses follow closely the level of the game sales. During the second quarter, depreciation of capitalized development expenses was related to Alan Wake 2 and FBC: Firebreak games. Other operating expenses, at EUR 4.4 million, increased by EUR 1.7 million as the marketing for CONTROL Resonant ramped up in Q2 2026. January–June 2026 In January‒June 2026, Remedy’s revenue decreased by 23.1% in relation to the comparison period, amounting to EUR 23.3 (30.3) million. Development fees were EUR 14.5 (18.1) million. Game sales and royalties were EUR 8.8 (12.2) million. The main sources of revenue during H1 2026 were development fees from Max Payne 1&2 remake and CONTROL Resonant. Alan Wake 2 continued to accrue royalties and Control as well as FBC: Firebreak accumulated game sales for the reporting period. In January‒June 2026, Remedy's EBITDA was EUR 0.5 (6.8) million and operating profit (EBIT) was EUR -2.9 (0.8) million. Materials and services expenses, at EUR 2.8 million, were EUR 3.4 million lower than in the comparison period. Personnel expenses, at EUR 13.1 million, were 4.9% higher than in the comparison period. Depreciation expenses were EUR 3.5 million, being EUR 2.5 million lower than in the comparison period. Other operating expenses, at EUR 7.1 million, also increased by EUR 2.2 million during H1 2026. This was driven by increasing marketing activity ahead of the game’s launch.
Page 9
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 9 (22) Cash flow and financial position Cash flow April–June 2026 In April‒June 2026, Remedy’s net cash flow was EUR -4.8 (-0.7) million. Cash flow from business operations was EUR -0.7 (3.1) million. Both the outgoing payments related to operating expenses as well as the incoming payments during the reporting period were at a lower level than in the comparison period, reflecting the reporting period’s lower revenue and timing of expense payments. In April‒June 2026, Remedy’s cash flow from investing activities amounted to EUR -3.8 (-3.3) million and cash flow from financing activities amounted to EUR -0.4 (-0.6) million. The payments related to investing activities were on a higher level as the amount of capitalized development costs increased from the comparison period. January–June 2026 In January‒June 2026, Remedy’s net cash flow was EUR -0.1 (-11.0) million. Cash flow from business operations amounted to EUR 7.6 (-3.5) million. In overall, the incoming payments were at a higher level during H1 2026 than on the comparison period. This was due to timing of the incoming payments, as the trade receivables decreased simultaneously during this period. In January‒June 2026, Remedy’s cash flow from investing activities was EUR -7.0 (-6.7) million and cash flow from financing activities was EUR -0.7 (-0.8) million. In the comparison period, the cash flow from financing activities was impacted by share subscriptions and the purchase of 2019 stock option rights. Financial position Remedy’s non-current assets on June 30, 2026, were EUR 46.9 (54.7) million in total. The decrease in non-current assets from the comparison period is largely due to depreciation and impairment expenses related to the capitalized game projects. Remedy has several projects, which product development costs, as well as the publishing rights of CONTROL franchise, are capitalized according to IFRS standards. The total amount of capitalized product development expenses was EUR 25.1 (29.4) million on June 30, 2026. Currently, the majority of the capitalized product development expenses are related to CONTROL Resonant. Other intangible assets amounted to EUR 7.5 (12.5) million and comprised of purchased CONTROL related publishing and distribution rights, of which the majority are also allocated to CONTROL Resonant. On June 30, 2026, Remedy’s cash position was EUR 9.6 (10.0) million and other current financial assets were EUR 20.0 (17.5) million. Other current financial assets include Remedy’s liquid cash management investments.
Page 10
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 10 (22) The company’s liabilities on June 30, 2026, amounted to EUR 30.2 (27.9) million. The amount contains EUR 15.6 million convertible loan liabilities related to the agreement Remedy entered with Tencent in September 2024. EUR 1.5 million of the agreement's total convertible loan liability is presented as part of the company's equity as required by the IFRS standards. Remedy’s balance sheet total on June 30, 2026, was EUR 85.1 (97.5) million and equity EUR 54.9 (69.6) million. The company’s equity ratio was 65.3% (72.8%) and net gearing -21.4% (-14.4%). Personnel, management and governance The number of the company’s personnel (headcount) was 379 (385) at the end of the period under review, decreasing by 1.6% on an annual basis. The average number of personnel (FTE) was 372 (370) during the reporting period, with a growth of 0.5% from the comparison period. Of the personnel, 53% represent 38 different nationalities, and the rest (47%) are Finnish. At the end of the period under review, the company’s Core Management Team comprised CEO Jean-Charles Gaudechon, CFO Santtu Kallionpää, Chief Product Officer Markus Mäki, Creative Director Sami Järvi, Creative Director Mikael Kasurinen, Chief Commercial Officer Johannes Paloheimo and Chief Technology Officer Mika Vehkala. Annual General Meeting Remedy’s Annual General Meeting was held on May 21, 2026, at the company’s office at Luomanportti 3, 02200 Espoo, Finland. The Annual General Meeting approved all proposals made to the Annual General Meeting in the form included in the notice to the Annual General Meeting. Among other things, the Annual General Meeting resolved to - adopt the company’s Financial Statements for 2025, - to discharge the members of the Board of Directors and the CEO from liability for the financial year 2025, - to approve the company’s Remuneration Report, - not to distribute a dividend for the financial period ended on December 31, 2025, and - to re-elect Markus Mäki, Henri Österlund, Kaisa Salakka, Sonja Ängeslevä and Kai Tavakka to the Board of Directors and to elect Sean Brennan as a new Board Member. At its organizing meeting held after the Annual General Meeting, the Board of Directors elected Henri Österlund as the Chairman of the Board of Directors.
Page 11
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 11 (22) Further information about the resolutions made by the Annual General Meeting can be found in Remedy’s Annual General Meeting resolutions release dated May 21, 2026, available on https://investors.remedygames.com/annual-general-meeting-2026/. Shares, shareholders and share-based incentive schemes Remedy’s shares are traded in Nasdaq Helsinki with the trading code REMEDY. The closing price of Remedy’s shares on the last trading day of the review period was 14.50 euros. January–June 2026 Highest share price, € Lowest share price, € Closing share price, € Volume-weighted average price, € Remedy 16.18 11.10 14.50 13.68 June 30, 2026 June 30, 2025 December 31, 2025 Market capitalization, € 197,061,540 202,151,484 206,574,855 Number of shareholders 16,778 17,008 16,365 Number of shares at the end of period 13,640,451 13,640,451 13,640,451 Number of shares outstanding at the end of period 13,590,451 13,640,451 13,590,451 Average number of shares outstanding within period 13,590,451 13,595,034 13,610,679 Average number of shares outstanding within period, diluted (IFRS)* 13,590,451 13,649,244 13,637,784 Average number of shares outstanding within period, diluted 13,590,451 13,735,617 13,680,971 Value of share turnover within period 13,783,741 15,152,290 27,742,810 Total number of traded shares within period 1,007,599 1,020,780 1,883,682 *Calculated according to International Financial Reporting Standards (IFRS). The company has one series of shares (ISIN: FI4000251897). The number of shares in the company was 13,640,451 on June 30, 2026, of which Remedy held 50,000 treasury shares. Excluding the treasury shares, the number of outstanding shares at the end of period was 13,590,451. On May 21, 2026, the Annual General Meeting granted the Board of Directors an authorisation to resolve on the issuance of new shares, treasury shares and option rights or other special rights to shares in one or several instalments either against payment or without payment so that the number of shares to be issued can be at maximum 1,000,000. On June 30, 2026, the authorization had not been used and thus, a total maximum of 1,000,000 new shares could be issued under the authorization on said date.
Page 12
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 12 (22) Major shareholders on June 30, 2026 Name Shares Percentage 1. Mäki Markus 3,197,000 23.4 2. Järvi Sami 560,000 4.1 3. Virtala Tero 288,125 2.1 4. Lehtinen Saku 198,500 1.5 5. Sijoitusrahasto Aktia Capital 188,807 1.4 6. Varma Mutual Pension Insurance Company 150,000 1.1 7. Evli Finnish Small Cap Fund 143,205 1.0 8. Proprius Partners Micro Finland (Non-Ucits) 130,000 1.0 9. Paloheimo Johannes 106,000 0.8 10. Pulkkinen Janne 100,000 0.7 10 largest shareholders total 5,061,637 37.1 Accendo Capital SICAV RAIF (nominee registered) 2,063,162 15.1 Other nominee registered 2,565,368 18.8 Other shares 3,900,284 28.6 Treasury shares 50,000 0.4 Total 13,640,451 100.0%
Page 13
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 13 (22) Option plans During the reporting period, Remedy has had six option plans directed to Remedy’s key persons: Option Plan 2020, Option Plan 2021, Option Plan 2022, Option Plan 2023, Option Plan 2024 and Option Plan 2025. The table below illustrates the key information about the option plans. More information about the option plans can be found on Remedy’s website at https://investors.remedygames.com/remuneration/. Key information about the option plans as of June 30, 2026 Option Plan Maximum number of option rights issued Number of allocated option rights Number of unexercised option rights Share subscription period Share subscription price, EUR Option Plan 2020 179,500 179,500 0 June 1, 2023 – May 31, 2026 22.21 Option Plan 2021 270,000 270,000 270,000 June 1, 2024 – May 31, 2027 47.09 Option Plan 2022 292,000 292,000 292,000 June 1, 2025 – May 31, 2028 26.64 Option Plan 2023 350,000 306,000 306,000 June 1, 2026 – May 31, 2029 27.31 Option Plan 2024 350,000 324,000 324,000 June 1, 2027 – May 31, 2030 19.76 Option Plan 2025 350,000 331,000 331,000 June 1, 2028 – May 31, 2031 16.66 Option Plan 2020 ended on May 31, 2026. Option Plan 2023 vested on June 1, 2026. Originally, a total number of 350,000 option rights 2023 were issued, of which Remedy will cancel a total of 44,000 option rights held by the company. The remaining 306,000 option rights entitle their holders to subscribe for a corresponding amount of company shares.
Page 14
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 14 (22) Risks and uncertainties The most substantial short-term risks and uncertainties are: • Remedy’s game development efforts may fail if the company is unable to develop its games within set mandates, such as release schedule, quality, and budget. Additionally, the company’s games may not generate sufficient sales after their release, even if well received and of high quality, thus generating less than estimated game revenue for Remedy. • Remedy has entered into long-term agreements with its partners related to game projects in development and game sales. If the company failed to satisfy key contract obligations, its partners could terminate their agreements with, or present claims to, the company. • Remedy is self-publishing its games based on fully owned IPs and is in this way taking more financing risk in game development. In case the self-published games are not successful and do not generate sufficient sales, Remedy carries the risk of the games not becoming profitable. • Remedy’s success depends significantly on its ability to hire, train, and retain skilled personnel. If the company fails in these areas, it will be unable to effectively conduct its business. • Remedy’s business is subject to economic, market, and geopolitical conditions, which are beyond its control. Possible significant fluctuations in currencies, especially USD exchange rate, could have effects on Remedy’s profitability. The above-mentioned risks might, if they materialize, have a significant negative impact on Remedy’s business operations, result, financial position, outlook and share price. Events after the end of the reporting period Remedy received the following flagging notifications after the reporting period. Mariatorp Oy’s total holding increased above the 5% threshold on July 7, 2026. Markus Mäki’s total holding decreased below the 20% threshold on July 7, 2026. Accendo Capital SICAV RAIF’s total holding decreased below the 15% threshold on July 7, 2026. There haven’t been any other significant events after the end of the review period.
Page 15
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 15 (22) Tables Consolidated statement of comprehensive income EUR thousand 4–6/2026 4–6/2025 1–6/2026 1–6/2025 1–12/2025 REVENUE 10,157 16,915 23,299 30,313 59,510 Development fees 6,353 7,396 14,542 18,146 32,947 Game sales and royalties 3,804 9,519 8,756 12,167 26,562 Other operating income 151 0 215 0 0 Materials and services -1,604 -3,636 -2,832 -6,220 -12,240 Game development related materials and services -1,151 -3,162 -2,058 -5,616 -10,471 Revenue related partner expenses -452 -474 -773 -605 -1,769 Personnel expenses -6,736 -6,429 -13,077 -12,465 -24,896 Depreciation, amortization and impairment -1,551 -4,667 -3,452 -5,955 -26,206 Other operating expenses -4,362 -2,643 -7,070 -4,838 -11,031 OPERATING PROFIT (LOSS) -3,946 -459 -2,916 835 -14,863 Financial income 488 458 501 724 1,150 Financial expenses -455 -559 -745 -1,020 -1,991 PROFIT (LOSS) BEFORE INCOME TAXES -3,912 -560 -3,160 539 -15,703 Income taxes 668 -7 393 -516 2,673 PROFIT (LOSS) FOR THE FINANCIAL YEAR -3,244 -568 -2,768 23 -13,030 OTHER COMPREHENSIVE INCOME (EXPENSE) Items that may be subsequently reclassified to profit or loss 0 0 0 0 0 Total other comprehensive income (expense) for the financial year 0 0 0 0 0 TOTAL COMPREHENSIVE INCOME (EXPENSE) FOR THE FINANCIAL YEAR -3,244 -568 -2,768 23 -13,030 PROFIT (LOSS) FOR THE FINANCIAL YEAR ATTRIBUTABLE TO OWNERS OF THE COMPANY -3,244 -568 -2,768 23 -13,030 EARNINGS PER SHARE Basic earnings per share, euro -0.24 -0.04 -0.20 0.00 -0.96 Diluted earnings per share, euro -0.24 -0.04 -0.20 0.00 -0.96
Page 16
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 16 (22) Consolidated statement of financial position EUR thousand June 30, 2026 June 30, 2025 December 31, 2025 ASSETS NON-CURRENT ASSETS Intangible assets 32,541 41,916 27,933 Tangible assets 2,020 2,919 2,369 Right-of-use assets 2,780 4,061 3,391 Non-current receivables 751 744 751 Deferred tax assets 8,759 5,071 8,308 TOTAL NON-CURRENT ASSETS 46,852 54,711 42,752 CURRENT ASSETS Trade and other receivables 8,635 15,211 15,402 Derivative financial instruments 0 21 0 Current financial assets 20,034 17,527 19,754 Cash and cash equivalents 9,562 10,029 9,641 TOTAL CURRENT ASSETS 38,231 42,789 44,797 TOTAL ASSETS 85,082 97,500 87,548
Page 17
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 17 (22) EUR thousand June 30, 2026 June 30, 2025 December 31, 2025 EQUITY AND LIABILITIES EQUITY Share capital 80 80 80 Share premium 38 38 38 Invested non-restricted equity reserve 58,169 58,855 58,169 Retained earnings (losses) -614 10,578 11,337 Profit (loss) for the financial year -2,768 23 -13,030 TOTAL EQUITY 54,905 69,573 56,594 LIABILITIES NON-CURRENT LIABILITIES Convertible bonds 15,003 13,473 14,838 Lease liabilities 1,496 2,790 2,123 Accrued expenses 648 600 0 Deferred tax liabilities 199 181 196 TOTAL NON-CURRENT LIABILITIES 17,346 17,044 17,157 CURRENT LIABILITIES Lease liabilities 1,338 1,288 1,306 Trade and other payables 11,494 9,595 12,491 TOTAL CURRENT LIABILITIES 12,831 10,883 13,797 TOTAL LIABILITIES 30,177 27,927 30,954 TOTAL EQUITY AND LIABILITIES 85,082 97,500 87,548
Page 18
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 18 (22) Condensed consolidated statement of cash flow EUR thousand 1–6/2026 1–6/2025 1–12/2025 Cash flow from operating activities 7,617 -3,482 4,513 Cash flow from investing activities* -6,978 -6,661 -13,646 Cash flow from financing activities -718 -824 -2,222 Liquid assets - opening balance 9,641 20,996 20,996 Change in liquid assets -79 -10,967 -11,356 Liquid assets - closing balance 9,562 10,029 9,641 *Includes capitalized development costs in January-June 2026 EUR -6,716 (in January-June 2025 EUR -6,105) thousand.
Page 19
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 19 (22) Consolidated statement of changes in equity Changes in shareholders’ equity 1–6/2026 Share capital Share premium Invested non- restricted equity reserve Retained earnings SHARE- HOLDERS’ EQUITY TOTAL EUR thousand Balance January 1, 2026 80 38 58,169 -1,693 56,594 Comprehensive income Profit (Loss) for the financial year -2,768 -2,768 Other comprehensive income Total comprehensive income -2,768 -2,768 Transactions with owners of the company Share options granted 1,079 1,079 Total transactions with owners 1,079 1,079 BALANCE June 30, 2026 80 38 58,169 -3,382 54,905 Changes in shareholders’ equity 1–6/2025 Share capital Share premium Invested non- restricted equity reserve Retained earnings SHARE- HOLDERS’ EQUITY TOTAL EUR thousand Balance January 1, 2025 80 38 58,344 10,065 68,527 Comprehensive income Profit (Loss) for the financial year 23 23 Other comprehensive income Total comprehensive income 23 23 Transactions with owners of the company Share options granted 1,223 1,223 Share issue and other share subscriptions 510 510 Purchase of option rights -710 -710 Total transactions with owners 510 513 1,023 BALANCE June 30, 2025 80 38 58,855 10,601 69,573
Page 20
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 20 (22) Notes to the Half-Year Financial Report January–June 2026 Accounting policies applied in the Half-Year Financial Report The Half-Year Financial Report has been prepared in accordance with IAS 34 'Interim Financial Reporting' while adhering to related IFRS standards applicable within the EU on June 30, 2026. The accounting policies of the Half-Year Financial Report are similar to the accounting policies applied in the Financial Statements according to IFRS for the period ended December 31, 2025. The disclosed figures have been rounded off from the accurate figures. The information presented in this Half-Year Financial Report is unaudited. Revenue breakdown per quarter EUR thousand 4–6/2026 1–3/2026 10–12/2025 7–9/2025 4–6/2025 Development fees 6,353 8,189 8,687 6,115 7,396 Game sales and royalties 3,804 4,952 8,354 6,041 9,519 Total 10,157 13,141 17,041 12,156 16,915 Fair value measurement and hierarchy of financial instruments Currently Remedy's financial assets and liabilities measured at fair value comprise of derivative assets and derivative liabilities and investments to equity funds. June 30, 2026 Carrying amount Fair value EUR thousand Level 1 Level 2 Level 3 Total Financial assets measured at fair value Investments to equity funds 20,034 20,034 - - 20,034 20,034 20,034 - - 20,034 Financial liabilities not measured at fair value Convertible bonds 15,003 - - 15,003 15,003 15,003 - - 15,003 15,003
Page 21
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 21 (22) December 31, 2025 Carrying amount Fair value EUR thousand Level 1 Level 2 Level 3 Total Financial assets measured at fair value Investments to equity funds 19,754 19,754 - - 19,754 19,754 19,754 - - 19,754 Financial liabilities not measured at fair value Convertible bonds 14,838 - - 14,838 14,838 14,838 - - 14,838 14,838 Level 1: fair value is calculated on the basis of quoted prices (unadjusted) in active markets for identical assets or liabilities that Remedy can access at the measurement date. Level 2: fair value is calculated on the basis of inputs other than quoted prices included in Level 1 that are observable for the asset or liability; either directly (i.e. as prices) or indirectly (i.e. derived from prices). Level 3: fair value is calculated on the basis of inputs for the asset or liability that are not based on observable market data (unobservable inputs). When measuring the fair value of an asset or a liability, Remedy uses observable market data as far as possible. Changes in tangible assets EUR thousand Machinery and equipment Other tangible assets Total 2026 2025 2026 2025 2026 2025 Cost Balance January 1 10,059 9,550 1,988 1,988 12,048 11,538 Additions 328 318 0 0 328 318 Balance June 30 10,387 9,868 1,988 1,988 12,375 11,856 Accumulated depreciation and impairment Balance January 1 -7,708 -6,233 -1,971 -1,947 -9,679 -8,180 Depreciation -662 -745 -15 -12 -676 -757 Balance June 30 -8,370 -6,978 -1,985 -1,959 -10,355 -8,937 Carrying amount on January 1 2,351 3,316 17 41 2,369 3,357 Carrying amount on June 30 2,017 2,890 3 29 2,020 2,919
Page 22
REMEDY ENTERTAINMENT PLC. LUOMANPORTTI 3, 02200 ESPOO, FINLAND 22 (22) Changes in intangible assets EUR thousand Capitalized development costs Other intangible assets Total 2026 2025 2026 2025 2026 2025 Cost Balance January 1 56,988 46,026 16,945 16,416 73,932 62,441 Additions 6,716 6,105 0 529 6,716 6,635 Balance June 30 63,704 52,131 16,945 16,945 80,648 69,076 Accumulated amortization and impairment Balance January 1 -36,819 -19,197 -9,181 -3,430 -45,999 -22,626 Amortization -1,824 -3,491 -284 -1,042 -2,108 -4,533 Balance June 30 -38,643 -22,688 -9,464 -4,472 -48,107 -27,160 Carrying amount on January 1 20,169 26,829 7,764 12,986 27,933 39,815 Carrying amount on June 30 25,061 29,443 7,480 12,473 32,541 41,916 Calculation formulas used for the indicators EBITDA: Operating profit (EBIT) + Depreciation, amortization and impairment Operating profit (EBIT): Profit (loss) before taxes and financial items Operating profit, % of revenue: Operating profit (EBIT) / revenue Net cash: Cash in hand and banks + liquid investments* - interest-bearing liabilities Net gearing, %: (Interest-bearing liabilities - cash in hand and at banks – liquid investments*) / shareholders’ equity Equity ratio, %: Shareholders’ equity / (balance sheet total - advances received) Capital Expenditures: Change in tangible and intangible assets added by depreciation of these assets *Liquid investments include Remedy’s liquid investments to equity funds. All of these investments are in cash, money market, or fixed income instruments. Espoo, August 11, 2026 Remedy Entertainment Plc Board of Directors